Ein Paarvergleich findet Originalpassagen, die den anderen Wirkstoff wörtlich nennen. Aussagen gelten für das jeweilige Präparat und seine Formulierung. Klassenbegriffe und abweichende Synonyme können fehlen. Kein Treffer bedeutet nicht, dass keine Wechselwirkung besteht.
RxNorm 05-Oct-2026 · geprüft 2026-10-26 · 1181 Präparate · 62955 Quellenpassagen · 167 strukturierte Aussagen. Automatisch aktualisiert, ohne menschliche Freigabe.
Wechselwirkungen · Norvir
Norvir 100 mg powder for oral suspension · Abschnitt 4.5 · PDF-Seite 20
HOS-086309 · Präparat HOS-083284
Immunosupressants
Cyclosporine, tacrolimus, everolimus Ritonavir dosed as a pharmacokinetic enhancer or as an antiretroviral agent inhibits
CYP3A4 and as a result is expected to increase the plasma concentrations of
cyclosporine, tacrolimus or everolimus. Careful monitoring of therapeutic and
adverse effects is recommended when these medicines are concomitantly
administered with ritonavir.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): tacrolimus (HOS-085202) everolimus (HOS-086310) cyclosporine (HOS-084512)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-11-11T18:35:00Z · SHA-256 82413695e61cf39577e85c47e382ee60197570a4ae72fe81d6e24e4211cd2d43 · Passage 8fcb9502c407bcb8fe8c827b9a7867c5ade280af937b8e491e27c6b13afb8e05 · Zeichen 45723–46283 im Abschnitt
Wechselwirkungen · Norvir
Norvir 100 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 53
HOS-086475 · Präparat HOS-083284
Immunosupressants
Cyclosporine, tacrolimus, everolimus Ritonavir dosed as a pharmacokinetic enhancer or as an antiretroviral agent inhibits
CYP3A4 and as a result is expected to increase the plasma concentrations of
cyclosporine, tacrolimus or everolimus. Careful monitoring of therapeutic and adverse
effects is recommended when these medicines are concomitantly administered with
ritonavir.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): tacrolimus (HOS-085202) everolimus (HOS-086310) cyclosporine (HOS-084512)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-11-11T18:35:00Z · SHA-256 82413695e61cf39577e85c47e382ee60197570a4ae72fe81d6e24e4211cd2d43 · Passage ddf69bc5196ee6b7c38c5de1755772a945526d00741ee3166f7a18209424edf2 · Zeichen 47677–48227 im Abschnitt
Wechselwirkungen · Vfend
VFEND 50 mg film-coated tablets VFEND 200 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 16
HOS-109478 · Präparat HOS-093201
Everolimus Although not studied, voriconazole Coadministration of voriconazole
[also P-gp substrate] is likely to significantly increase and everolimus is not
the plasma concentrations of recommended because
everolimus. voriconazole is expected to
significantly increase everolimus
concentrations (see section 4.4).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): everolimus (HOS-086310)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-07-21T15:15:00Z · SHA-256 e91b23f050e51d641bef6be84ca7a49bb0e71d249b5c23f29243dda478d37eaf · Passage 93f869f52972622986560029cecaaf2dbb9e06e28ad47352ac77836d28d94f18 · Zeichen 24231–24833 im Abschnitt
Wechselwirkungen · Vfend
VFEND 200 mg powder for solution for infusion · Abschnitt 4.5 · PDF-Seite 48
HOS-109550 · Präparat HOS-093201
Everolimus Although not studied, voriconazole Coadministration of voriconazole
[also P-gp substrate] is likely to significantly increase and everolimus is not
the plasma concentrations of recommended because
everolimus. voriconazole is expected to
significantly increase everolimus
concentrations (see section 4.4).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): everolimus (HOS-086310)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-07-21T15:15:00Z · SHA-256 e91b23f050e51d641bef6be84ca7a49bb0e71d249b5c23f29243dda478d37eaf · Passage 93f869f52972622986560029cecaaf2dbb9e06e28ad47352ac77836d28d94f18 · Zeichen 24735–25337 im Abschnitt
Wechselwirkungen · Vfend
VFEND 40 mg/ml powder for oral suspension · Abschnitt 4.5 · PDF-Seite 80
HOS-109615 · Präparat HOS-093201
Everolimus Although not studied, voriconazole Coadministration of voriconazole
[also P-gp substrate] is likely to significantly increase and everolimus is not
the plasma concentrations of recommended because
everolimus. voriconazole is expected to
significantly increase everolimus
concentrations (see section 4.4).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): everolimus (HOS-086310)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-07-21T15:15:00Z · SHA-256 e91b23f050e51d641bef6be84ca7a49bb0e71d249b5c23f29243dda478d37eaf · Passage 93f869f52972622986560029cecaaf2dbb9e06e28ad47352ac77836d28d94f18 · Zeichen 24261–24863 im Abschnitt
Wechselwirkungen · Emend
EMEND 125 mg hard capsules EMEND 80 mg hard capsules · Abschnitt 4.5 · PDF-Seite 5
HOS-112511 · Präparat HOS-093697
Effect aprepitant on the pharmacokinetics of other active substances
CYP3A4 inhibition
As a moderate inhibitor of CYP3A4, aprepitant (125 mg/80 mg) can increase plasma concentrations of
co-administered active substances that are metabolised through CYP3A4. The total exposure of orally
administered CYP3A4 substrates may increase up to approximately 3-fold during the 3-day treatment
with EMEND; the effect of aprepitant on the plasma concentrations of intravenously administered
CYP3A4 substrates is expected to be smaller. EMEND must not be used concurrently with pimozide,
terfenadine, astemizole, or cisapride (see section 4.3). Inhibition of CYP3A4 by aprepitant could result
in elevated plasma concentrations of these active substances, potentially causing serious or
life-threatening reactions. Caution is advised during concomitant administration of EMEND and orally
administered active substances that are metabolised primarily through CYP3A4 and with a narrow
therapeutic range, such as cyclosporine, tacrolimus, sirolimus, everolimus, alfentanil, diergotamine,
ergotamine, fentanyl, and quinidine (see section 4.4).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): alfentanil (HOS-109375) cisapride (HOS-085610) quinidine (HOS-085593) tacrolimus (HOS-085202) pimozide (HOS-085600) everolimus (HOS-086310) astemizole (HOS-085608) sirolimus (HOS-085172) fentanyl (HOS-086196) ergotamine (HOS-086154) terfenadine (HOS-085607) cyclosporine (HOS-084512)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-10-24T11:24:00Z · SHA-256 afd6062a51e59b36e448c9117685894e4529fcde2f5e673f4401f91bb32d7081 · Passage 95169de188fddd2d62217733cbc8b18b68fe7db2d6460ff4dc5aa2b0e655690d · Zeichen 490–1616 im Abschnitt
Wechselwirkungen · Emend
EMEND 125 mg hard capsules EMEND 80 mg hard capsules · Abschnitt 4.5 · PDF-Seite 5
HOS-112519 · Präparat HOS-093697
Immunosuppressants
During the 3-day CINV regimen, a transient moderate increase followed by a mild decrease in
exposure of immunosuppressants metabolised by CYP3A4 (e.g., cyclosporine, tacrolimus, everolimus
and sirolimus) is expected. Given the short duration of the 3-day regimen and the time-dependent
limited changes in exposure, dose reduction of the immunosuppressant is not recommended during the
3 days of co-administration with EMEND.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): tacrolimus (HOS-085202) everolimus (HOS-086310) sirolimus (HOS-085172) cyclosporine (HOS-084512)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-10-24T11:24:00Z · SHA-256 afd6062a51e59b36e448c9117685894e4529fcde2f5e673f4401f91bb32d7081 · Passage d716b4ab0ac7e8e54e8a04ed18ca52ab22872da60953c2f0bc723b09e2008fea · Zeichen 4096–4539 im Abschnitt
Wechselwirkungen · Emend
EMEND 125 mg powder for oral suspension · Abschnitt 4.5 · PDF-Seite 22
HOS-112572 · Präparat HOS-093697
Effect of aprepitant on the pharmacokinetics of other active substances
CYP3A4 inhibition
As a moderate inhibitor of CYP3A4, aprepitant (125 mg/80 mg) can increase plasma concentrations of
co-administered active substances that are metabolised through CYP3A4. The total exposure of orally
administered CYP3A4 substrates may increase up to approximately 3-fold during the 3-day treatment
with EMEND; the effect of aprepitant on the plasma concentrations of intravenously administered
CYP3A4 substrates is expected to be smaller. EMEND must not be used concurrently with pimozide,
terfenadine, astemizole, or cisapride (see section 4.3). Inhibition of CYP3A4 by aprepitant could result
in elevated plasma concentrations of these active substances, potentially causing serious or
life-threatening reactions. Caution is advised during concomitant administration of EMEND and orally
administered active substances that are metabolised primarily through CYP3A4 and with a narrow
therapeutic range, such as cyclosporine, tacrolimus, sirolimus, everolimus, alfentanil, diergotamine,
ergotamine, fentanyl, and quinidine (see section 4.4).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): alfentanil (HOS-109375) cisapride (HOS-085610) quinidine (HOS-085593) tacrolimus (HOS-085202) pimozide (HOS-085600) everolimus (HOS-086310) astemizole (HOS-085608) sirolimus (HOS-085172) fentanyl (HOS-086196) ergotamine (HOS-086154) terfenadine (HOS-085607) cyclosporine (HOS-084512)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-10-24T11:24:00Z · SHA-256 afd6062a51e59b36e448c9117685894e4529fcde2f5e673f4401f91bb32d7081 · Passage b50d17ed63c48d4d594d584aa63f6b0c29730ab2069a1d8a4a7e4e6f403046fb · Zeichen 431–1560 im Abschnitt
Wechselwirkungen · Emend
EMEND 125 mg powder for oral suspension · Abschnitt 4.5 · PDF-Seite 23
HOS-112578 · Präparat HOS-093697
Immunosuppressants
During the 3-day CINV regimen, a transient moderate increase followed by a mild decrease in
exposure of immunosuppressants metabolised by CYP3A4 (e.g., cyclosporine, tacrolimus, everolimus
and sirolimus) is expected. Given the short duration of the 3-day regimen and the time-dependent
limited changes in exposure, dose reduction of the immunosuppressant is not recommended during the
3 days of co-administration with EMEND.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): tacrolimus (HOS-085202) everolimus (HOS-086310) sirolimus (HOS-085172) cyclosporine (HOS-084512)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-10-24T11:24:00Z · SHA-256 afd6062a51e59b36e448c9117685894e4529fcde2f5e673f4401f91bb32d7081 · Passage d716b4ab0ac7e8e54e8a04ed18ca52ab22872da60953c2f0bc723b09e2008fea · Zeichen 4096–4539 im Abschnitt
Wechselwirkungen · Prezista
PREZISTA 100 mg/ml oral suspension · Abschnitt 4.5 · PDF-Seite 19
HOS-116392 · Präparat HOS-094447
Everolimus Concomitant use of everolimus or
Irinotecan irinotecan and boosted PREZISTA
is not recommended.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): everolimus (HOS-086310) irinotecan (HOS-112102)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2024-07-26T09:44:00Z · SHA-256 457dafbe8b3b9cee45b9ca7b46919ded598e0d0cd16715525d161e54f80b9117 · Passage 9129a3e633996192f47cda0e9e8d18163404eaa6ca0c83c5cfc19495421a65a5 · Zeichen 51636–51946 im Abschnitt
Wechselwirkungen · Prezista
PREZISTA 100 mg/ml oral suspension · Abschnitt 4.5 · PDF-Seite 21–22
HOS-116415 · Präparat HOS-094447
21
Rosuvastatin rosuvastatin AUC ↑ 48%║ When administration of
10 mg once daily rosuvastatin Cmax ↑ 144%║ rosuvastatin and boosted
║
based on published data with PREZISTA is required, it is
darunavir/ritonavir recommended to start with the
lowest possible dose of
rosuvastatin AUC ↑ 93%§ rosuvastatin and titrate up to the
rosuvastatin Cmax ↑ 277%§ desired clinical effect while
rosuvastatin Cmin ND§ monitoring for safety.
§
with darunavir/cobicistat 800/150 mg
OTHER LIPID MODIFYING AGENTS
Lomitapide Based on theoretical considerations Co-administration is
boosted PREZISTA is expected to contraindicated (see section 4.3).
increase the exposure of lomitapide when
co-administered.
(CYP3A inhibition)
H2-RECEPTOR ANTAGONISTS
Ranitidine # Boosted PREZISTA can be
darunavir AUC ↔
150 mg twice daily #
darunavir Cmin ↔ co-administered with H2-receptor
#
darunavir Cmax ↔ antagonists without dose
adjustments.
IMMUNOSUPPRESSANTS
Ciclosporin Not studied. Exposure to these Therapeutic drug monitoring of the
Sirolimus immunosuppressants will be increased immunosuppressive agent must be
Tacrolimus when co-administered with boosted done when co-administration
PREZISTA. occurs.
(CYP3A inhibition)
Everolimus Concomitant use of everolimus
and boosted PREZISTA is not
recommended.
INHALED BETA AGONISTS
Salmeterol Not studied. Concomitant use of Concomitant use of salmeterol and
salmeterol and boosted darunavir may boosted PREZISTA is not
increase plasma concentrations of recommended. The combination
salmeterol. may result in increased risk of
cardiovascular adverse event with
salmeterol, including QT
prolongation, palpitations and
sinus tachycardia.
NARCOTIC ANALGESICS / TREATMENT OF OPIOID DEPENDENCE
Methadone R(-) methadone AUC ↓ 16% No adjustment of methadone
individual dose ranging R(-) methadone Cmin ↓ 15% dosage is required when initiating
from 55 mg to 150 mg R(-) methadone Cmax ↓ 24% co-administration with boosted
once daily PREZISTA. However, adjustment
PREZISTA/cobicistat may, in contrast, of the methadone dose may be
increase methadone plasma necessary when concomitantly
concentrations (see cobicistat SmPC). administered for a longer period of
time. Therefore, clinical
monitoring is recommended, as
maintenance therapy may need to
be adjusted in some patients.
Buprenorphine/naloxone buprenorphine AUC ↓ 11% The clinical relevance of the
8/2 mg–16/4 mg once buprenorphine Cmin ↔ increase in norbuprenorphine
daily buprenorphine Cmax ↓ 8% pharmacokinetic parameters has
norbuprenorphine AUC ↑ 46% not been established. Dose
norbuprenorphine Cmin ↑ 71% adjustment for buprenorphine may
norbuprenorphine Cmax ↑ 36% not be necessary when
naloxone AUC ↔ co-administered with boosted
PREZISTA but a careful clinical
naloxone Cmin ND
monitoring for signs of opiate
naloxone Cmax ↔ toxicity is recommended.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): methadone (HOS-086198) lomitapide (HOS-086160) cobicistat (HOS-088111) rosuvastatin (HOS-086307) buprenorphine (HOS-086193) salmeterol (HOS-086285) tacrolimus (HOS-085202) ranitidine (HOS-085660) everolimus (HOS-086310) naloxone (HOS-109490) sirolimus (HOS-085172) ritonavir (HOS-084521)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2024-07-26T09:44:00Z · SHA-256 457dafbe8b3b9cee45b9ca7b46919ded598e0d0cd16715525d161e54f80b9117 · Passage 5acbdf6c1f8cbcfa7417e6f43148a46845265b80041528b8854960cce50aae89 · Zeichen 63548–68815 im Abschnitt
Wechselwirkungen · Prezista
PREZISTA 75 mg film-coated tablets PREZISTA 150 mg film-coated tablets PREZISTA 600 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 61
HOS-116526 · Präparat HOS-094447
Everolimus Concomitant use of everolimus or
Irinotecan irinotecan and PREZISTA
co-administered with low dose
ritonavir is not recommended.
ANTIPSYCHOTICS/NEUROLEPTICS
Quetiapine Not studied. PREZISTA is expected to Concomitant administration of
increase these antipsychotic plasma PREZISTA with low dose
concentrations. ritonavir and quetiapine is
(CYP3A inhibition) contraindicated as it may increase
quetiapine-related toxicity.
Increased concentrations of
quetiapine may lead to coma (see
section 4.3).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): quetiapine (HOS-086150) lead (HOS-085592) everolimus (HOS-086310) ritonavir (HOS-084521) irinotecan (HOS-112102)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2024-07-26T09:44:00Z · SHA-256 457dafbe8b3b9cee45b9ca7b46919ded598e0d0cd16715525d161e54f80b9117 · Passage 18aed816dca48176025dcb58213f9af8485c4e13d8d817997ae2993ed50f29ba · Zeichen 41969–43232 im Abschnitt
Wechselwirkungen · Prezista
PREZISTA 75 mg film-coated tablets PREZISTA 150 mg film-coated tablets PREZISTA 600 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 63–64
HOS-116529 · Präparat HOS-094447
63
Rosuvastatin rosuvastatin AUC ↑ 48%║ When administration of
10 mg once daily rosuvastatin Cmax ↑ 144%║ rosuvastatin and PREZISTA
║
based on published data with co-administered with low dose
darunavir/ritonavir ritonavir is required, it is
recommended to start with the
lowest possible dose of
rosuvastatin and titrate up to the
desired clinical effect while
monitoring for safety.
OTHER LIPID MODIFYING AGENTS
Lomitapide Based on theoretical considerations Co-administration is
boosted PREZISTA is expected to contraindicated (see section 4.3).
increase the exposure of lomitapide when
co-administered.
(CYP3A inhibition)
H2-RECEPTOR ANTAGONISTS
Ranitidine # PREZISTA co-administered with
darunavir AUC ↔
150 mg twice daily #
darunavir Cmin ↔ low dose ritonavir can be
#
darunavir Cmax ↔ co-administered with H2-receptor
antagonists without dose
adjustments.
IMMUNOSUPPRESSANTS
Ciclosporin Not studied. Exposure to these Therapeutic drug monitoring of the
Sirolimus immunosuppressants will be increased immunosuppressive agent must be
Tacrolimus when co-administered with PREZISTA done when co-administration
co-administered with low dose ritonavir. occurs.
(CYP3A inhibition)
Everolimus Concomitant use of everolimus
and PREZISTA co-administered
with low dose ritonavir is not
recommended.
INHALED BETA AGONISTS
Salmeterol Not studied. Concomitant use ofConcomitant use of salmeterol and
salmeterol and darunavir co-administered
PREZISTA co-administered with
with low dose ritonavir may increase
low dose ritonavir is not
plasma concentrations of salmeterol.
recommended. The combination
may result in increased risk of
cardiovascular adverse event with
salmeterol, including QT
prolongation, palpitations and
sinus tachycardia.
NARCOTIC ANALGESICS / TREATMENT OF OPIOID DEPENDENCE
Methadone R(-) methadone AUC ↓ 16% No adjustment of methadone
individual dose ranging R(-) methadone Cmin ↓ 15% dosage is required when initiating
from 55 mg to 150 mg R(-) methadone Cmax ↓ 24% co-administration with
once daily PREZISTA/ritonavir. However,
increased methadone dose may be
necessary when concomitantly
administered for a longer period of
time due to induction of
metabolism by ritonavir.
Therefore, clinical monitoring is
recommended, as maintenance
therapy may need to be adjusted in
some patients.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): methadone (HOS-086198) lomitapide (HOS-086160) rosuvastatin (HOS-086307) salmeterol (HOS-086285) tacrolimus (HOS-085202) ranitidine (HOS-085660) everolimus (HOS-086310) sirolimus (HOS-085172) ritonavir (HOS-084521)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2024-07-26T09:44:00Z · SHA-256 457dafbe8b3b9cee45b9ca7b46919ded598e0d0cd16715525d161e54f80b9117 · Passage f2f65869b04ef808ebdc5d5e920ff573b17a50545ae43721f20f184c9d93d8d0 · Zeichen 54354–58869 im Abschnitt
Wechselwirkungen · Prezista
PREZISTA 400 mg film-coated tablets PREZISTA 800 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 101
HOS-116616 · Präparat HOS-094447
Everolimus Concomitant use of everolimus or
Irinotecan irinotecan and boosted PREZISTA
is not recommended.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): everolimus (HOS-086310) irinotecan (HOS-112102)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2024-07-26T09:44:00Z · SHA-256 457dafbe8b3b9cee45b9ca7b46919ded598e0d0cd16715525d161e54f80b9117 · Passage 9129a3e633996192f47cda0e9e8d18163404eaa6ca0c83c5cfc19495421a65a5 · Zeichen 51108–51418 im Abschnitt
Wechselwirkungen · Prezista
PREZISTA 400 mg film-coated tablets PREZISTA 800 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 103–104
HOS-116619 · Präparat HOS-094447
103
Rosuvastatin rosuvastatin AUC ↑ 48%║ When administration of
10 mg once daily rosuvastatin Cmax ↑ 144%║ rosuvastatin and boosted
║
based on published data with PREZISTA is required, it is
darunavir/ritonavir recommended to start with the
lowest possible dose of
rosuvastatin AUC ↑ 93%§ rosuvastatin and titrate up to the
rosuvastatin Cmax ↑ 277%§ desired clinical effect while
rosuvastatin Cmin ND§ monitoring for safety.
§
with darunavir/cobicistat 800/150 mg
OTHER LIPID MODIFYING AGENTS
Lomitapide Based on theoretical considerations Co-administration is
boosted PREZISTA is expected to contraindicated (see section 4.3).
increase the exposure of lomitapide when
co-administered.
(CYP3A inhibition)
H2-RECEPTOR ANTAGONISTS
Ranitidine # Boosted PREZISTA can be
darunavir AUC ↔
150 mg twice daily #
darunavir Cmin ↔ co-administered with H2-receptor
#
darunavir Cmax ↔ antagonists without dose
adjustments.
IMMUNOSUPPRESSANTS
Ciclosporin Not studied. Exposure to these Therapeutic drug monitoring of the
Sirolimus immunosuppressants will be increased immunosuppressive agent must be
Tacrolimus when co-administered with boosted done when co-administration
PREZISTA. occurs.
(CYP3A inhibition)
Everolimus Concomitant use of everolimus
and boosted PREZISTA is not
recommended.
INHALED BETA AGONISTS
Salmeterol Not studied. Concomitant use of Concomitant use of salmeterol and
salmeterol and boosted darunavir may boosted PREZISTA is not
increase plasma concentrations of recommended. The combination
salmeterol. may result in increased risk of
cardiovascular adverse event with
salmeterol, including QT
prolongation, palpitations and
sinus tachycardia.
NARCOTIC ANALGESICS / TREATMENT OF OPIOID DEPENDENCE
Methadone R(-) methadone AUC ↓ 16% No adjustment of methadone
individual dose ranging R(-) methadone Cmin ↓ 15% dosage is required when initiating
from 55 mg to 150 mg R(-) methadone Cmax ↓ 24% co-administration with boosted
once daily PREZISTA. However, adjustment
PREZISTA/cobicistat may, in contrast, of the methadone dose may be
increase methadone plasma necessary when concomitantly
concentrations (see cobicistat SmPC). administered for a longer period of
time. Therefore, clinical
monitoring is recommended, as
maintenance therapy may need to
be adjusted in some patients.
Buprenorphine/naloxone buprenorphine AUC ↓ 11% The clinical relevance of the
8/2 mg–16/4 mg once buprenorphine Cmin ↔ increase in norbuprenorphine
daily buprenorphine Cmax ↓ 8% pharmacokinetic parameters has
norbuprenorphine AUC ↑ 46% not been established. Dose
norbuprenorphine Cmin ↑ 71% adjustment for buprenorphine may
norbuprenorphine Cmax ↑ 36% not be necessary when
naloxone AUC ↔ co-administered with boosted
PREZISTA but a careful clinical
naloxone Cmin ND
monitoring for signs of opiate
naloxone Cmax ↔ toxicity is recommended.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): methadone (HOS-086198) lomitapide (HOS-086160) cobicistat (HOS-088111) rosuvastatin (HOS-086307) buprenorphine (HOS-086193) salmeterol (HOS-086285) tacrolimus (HOS-085202) ranitidine (HOS-085660) everolimus (HOS-086310) naloxone (HOS-109490) sirolimus (HOS-085172) ritonavir (HOS-084521)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2024-07-26T09:44:00Z · SHA-256 457dafbe8b3b9cee45b9ca7b46919ded598e0d0cd16715525d161e54f80b9117 · Passage 6e9aabce398149840c7621950bc6562a692bbfc641caaabe022d97e86d869ebf · Zeichen 62955–68223 im Abschnitt
Wechselwirkungen · Advagraf
Advagraf 0.5 mg prolonged-release hard capsules Advagraf 1 mg prolonged-release hard capsules Advagraf 3 mg prolonged-release hard capsules Advagraf 5 mg prolonged-release hard capsules · Abschnitt 4.5 · PDF-Seite 13
HOS-116840 · Präparat HOS-094481
Concomitant administration of tacrolimus with a mammalian target of rapamycin (mTOR) inhibitor
(e.g., sirolimus, everolimus) may increase the risk of thrombotic microangiopathy (including
haemolytic uraemic syndrome and thrombotic thrombocytopenic purpura) (see section 4.4).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): everolimus (HOS-086310) sirolimus (HOS-085172)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-02-27T10:10:00Z · SHA-256 0ed42bc08ffe6bd7e6c8ed94445bdb8b8c9971dabe41ef3a899ec75fc2f97c0e · Passage 8845116d787145b8a817449a98d00818198e3182726dab33cd9035bbdcbe70ca · Zeichen 16560–16835 im Abschnitt
Wechselwirkungen · Ivemend
IVEMEND 150 mg powder for solution for infusion. · Abschnitt 4.5 · PDF-Seite 7
HOS-117436 · Präparat HOS-094609
Effect of fosaprepitant on the pharmacokinetics of other active substances
CYP3A4 inhibition
As a weak inhibitor of CYP3A4, the fosaprepitant 150 mg single dose can cause a transient increase in
plasma concentrations of co-administered active substances that are metabolised through CYP3A4.
The total exposure of CYP3A4 substrates may increase up to 2-fold on Days 1 and 2 after co-
administration with a single 150 mg fosaprepitant dose. Fosaprepitant must not be used concurrently
with pimozide, terfenadine, astemizole, or cisapride. Inhibition of CYP3A4 by fosaprepitant could
result in elevated plasma concentrations of these active substances, potentially causing serious or life-
threatening reactions (see section 4.3). Caution is advised during concomitant administration of
fosaprepitant and active substances that are metabolised primarily through CYP3A4 and with a narrow
therapeutic range, such as ciclosporin, tacrolimus, sirolimus, everolimus, alfentanil, diergotamine,
ergotamine, fentanyl, and quinidine (see section 4.4).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): alfentanil (HOS-109375) cisapride (HOS-085610) quinidine (HOS-085593) tacrolimus (HOS-085202) pimozide (HOS-085600) everolimus (HOS-086310) astemizole (HOS-085608) sirolimus (HOS-085172) fentanyl (HOS-086196) ergotamine (HOS-086154) terfenadine (HOS-085607)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-11-05T14:57:00Z · SHA-256 9e19bc1fa93d788029c9702424aacb9622fe408d4db1dbe0bc9e0ad1d449f179 · Passage a3d72089ac8f22106e064a5b53eea12b3862e18df89fd2a25aacaa574d8c8b78 · Zeichen 1419–2458 im Abschnitt
Wechselwirkungen · Ivemend
IVEMEND 150 mg powder for solution for infusion. · Abschnitt 4.5 · PDF-Seite 7–8
HOS-117442 · Präparat HOS-094609
7
Immunosuppressants
Following a single 150 mg fosaprepitant dose, a transient moderate increase for two days possibly
followed by a mild decrease in exposure of immunosuppressants metabolised by CYP3A4 (e.g.,
ciclosporin, tacrolimus, everolimus and sirolimus) is expected. Given the short duration of increased
exposure, dose reduction of the immunosuppressant based on Therapeutic Dose Monitoring is not
recommended on the day of and the day after administration of IVEMEND.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): tacrolimus (HOS-085202) everolimus (HOS-086310) sirolimus (HOS-085172)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-11-05T14:57:00Z · SHA-256 9e19bc1fa93d788029c9702424aacb9622fe408d4db1dbe0bc9e0ad1d449f179 · Passage 0b47cbcadb31cee9e654a7f8cc9b41b46165a28ed209e01e5ccb58f058573d55 · Zeichen 3790–4267 im Abschnitt
Wechselwirkungen · Ranexa (previously Latixa)
Ranexa 375 mg prolonged-release tablets · Abschnitt 4.5 · PDF-Seite 4
HOS-118255 · Präparat HOS-094791
Dose adjustment of sensitive CYP3A4 substrates (e.g. simvastatin, lovastatin) and CYP3A4 substrates
with a narrow therapeutic range (e.g. ciclosporin, tacrolimus, sirolimus, everolimus) may be required
as RANEXA may increase plasma concentrations of these drugs.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): lovastatin (HOS-086157) simvastatin (HOS-086158) tacrolimus (HOS-085202) everolimus (HOS-086310) sirolimus (HOS-085172)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2022-08-11T13:07:00Z · SHA-256 0a3c1ac3a3e7045516969928ccd0918506379303d254770ac2a2d732c1bd1d40 · Passage 42333281082168baf3e258a472cc235246a9d9fb4f172fbca1447d41e84cb85c · Zeichen 2630–2892 im Abschnitt
Wechselwirkungen · Ranexa (previously Latixa)
Ranexa 375 mg prolonged-release tablets · Abschnitt 4.5 · PDF-Seite 5
HOS-118262 · Präparat HOS-094791
Tacrolimus, ciclosporin, sirolimus, everolimus: Increased plasma concentrations of tacrolimus, a
CYP3A4 substrate, have been observed in patients after ranolazine administration. It is recommended
that tacrolimus blood levels are monitored when co-administering Ranexa and tacrolimus and that
tacrolimus dosage is adjusted accordingly. This is also recommended for other CYP3A4 substrates
with a narrow therapeutic range (e.g., ciclosporin, sirolimus, everolimus).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): tacrolimus (HOS-085202) everolimus (HOS-086310) sirolimus (HOS-085172)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2022-08-11T13:07:00Z · SHA-256 0a3c1ac3a3e7045516969928ccd0918506379303d254770ac2a2d732c1bd1d40 · Passage 0fe27dbe872909b20752f1ab6a1443caaa4f0ed6004808e6f917e6d17e6ff3be · Zeichen 4716–5180 im Abschnitt
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.